7.81k followers • 30 symbols Watchlist by Yahoo Finance
Follow this list to discover and track stocks that have set 52-week highs within the last week. This list is generated daily, ranked by market cap and limited to the top 30 stocks that meet the criteria.
Bristol-Myers Squibb Company
Capital One Financial Corporation
TAL Education Group
Citizens Financial Group, Inc.
Nomura Holdings, Inc.
Campbell Soup Company
Alnylam Pharmaceuticals, Inc.
Vipshop Holdings Limited
The Stars Group Inc.
United Microelectronics Corporation
Sibanye Gold Limited
Western Alliance Bancorporation
Pinnacle Financial Partners, Inc.
Companhia Paranaense de Energia - COPEL
Pan American Silver Corp.
Tenet Healthcare Corporation
(Bloomberg) -- A U.S. Supreme Court justice temporarily blocked subpoenas that would force Deutsche Bank AG and Capital One Financial Corp. to turn over years of President Donald Trump’s financial documents to two House committees.Justice Ruth Bader Ginsburg put the subpoenas on hold until Dec. 13. The justices are already scheduled to discuss at a private conference that day whether to take up a separate challenge by Trump to a subpoena by a New York prosecutor for his tax returns.The request Ginsburg acted on Friday stems from a Dec. 3 federal appeals court decision that largely rejected Trump’s contentions that lawmakers were exceeding their authority and intruding on his privacy by sending subpoenas to the banks.The case is Trump v. Deutsche Bank, 19A640.To contact the reporter on this story: Greg Stohr in Washington at firstname.lastname@example.orgTo contact the editors responsible for this story: Joe Sobczyk at email@example.com, Laurie Asséo, Ros KrasnyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
(Bloomberg) -- An experimental therapy from Bluebird Bio Inc. and Bristol-Myers Squibb Co. benefited more than 80% of patients nearing death from an advanced form of blood cancer in a pivotal study, clearing a hurdle in its path to U.S. approval.A single high-dose infusion of the personalized medicine known as bb2121 generated a response in 44 of 54 patients with multiple myeloma, including 19 who had a complete response, the companies said in a statement Friday. Patients went a median of 11.3 months before the cancer progressed, topping expectations that it needed to stop the disease for at least six months to gain approval from the U.S. Food and Drug Administration.Bluebird shares briefly jumped in late trading on Friday before surrendering most of their gains. The recently-issued CVR given in connection with the closing of Bristol-Myers’ deal with Celgene, known by the ticker BMY-R, rose 8.3%.The companies divulged the findings on the eve of the American Society of Hematology’s annual meeting in Orlando, Florida, where GlaxoSmithKline Plc., Regeneron Pharmaceuticals Inc. and Bristol’s own Celgene unit will present data on competing approaches. Cambridge, Massachusetts-based Bluebird and New York-based Bristol-Myers are scheduled to give an update on their next-generation therapy, bb21217, on Monday, while hotly anticipated results from competitor Johnson & Johnson’s Nanjing Legend Biotech-partnered therapy will take the spotlight that morning.The depth and the durability of the data “puts us in very good stead around any of the antibodies as well as other gene therapies,” Bluebird Chief Executive Officer Nick Leschly said. “We feel quite good about it, and that’s why we’re sprinting toward submission and driving toward earlier lines of therapy.”Positive results from the study, dubbed KarMMa, could lead to the first approval of the approach called CAR-T for patients with multiple myeloma, a deadly form of cancer found in white blood cells, wrote Raju Prasad, an analyst at William Blair, in a note. A response rate greater than 80% that can hold off the disease for at least 11 months would be well-received by doctors who might otherwise be wary of potential high costs and an aggressive approach, said Yaron Werber, an analyst at Cowen & Co.The approach known as CAR-T is already approved for a hard-to-treat form of pediatric leukemia and diffuse large B cell lymphoma, both blood cancers that are much less common than the multiple myeloma, which is diagnosed in about 30,000 Americans each year. Bluebird and Bristol’s therapy involves removing infection-fighting T cells from the blood, altering them to recognize a protein known as BCMA that is found in multiple myeloma cells, then putting them back into the patient to kill the cancer.(Updates with stock-price movement in third paragraph)\--With assistance from Tatiana Darie.To contact the reporters on this story: Bailey Lipschultz in New York at firstname.lastname@example.org;Michelle Fay Cortez in Minneapolis at email@example.comTo contact the editors responsible for this story: Catherine Larkin at firstname.lastname@example.org, Mark Schoifet, Timothy AnnettFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Leveraging 5G Ultra Wideband network, Verizon (VZ) partners with Sony to promote next-gen live sports viewing experience with excellent wireless connectivity, low-latency and high-definition video.
NuVasive (NUVA) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Zacks.com featured highlights include: Target, Medtronic Public, Arconic, Science Applications International and Bristol-Myers Squibb
Achieving your retirement goals takes a much different investing approach than regular stock trading, from smartly managing risk to keeping emotions in check.
(Bloomberg) -- President Donald Trump asked the U.S. Supreme Court to hear his challenge to a House subpoena for financial records held by his accounting firm, saying lawmakers are exceeding their authority with a broad probe into his personal and business affairs.The appeal comes in one of three subpoena cases speeding toward a potential Supreme Court showdown. The justices are already scheduled to discuss at their Dec. 13 private conference whether to take up Trump’s challenge to a subpoena by a New York prosecutor for his tax returns.In addition, the president’s lawyers have said they will file an emergency request Thursday asking the court to temporarily stop Deutsche Bank AG and Capital One Financial Corp. from handing over Trump’s financial records to the House.The cases aren’t directly tied to the ongoing House impeachment probe, which centers on Trump’s push to have Ukraine announce investigations that could help him politically. The cases will test the justices’ willingness to shield the president from investigations into his personal and business affairs. Federal appeals courts ruled against Trump in all three disputes.The Supreme Court has already temporarily blocked the House subpoena in the case that was the subject of Trump’s formal appeal Thursday, involving the accounting firm Mazars USA.‘All Statements’The demand from the House Oversight and Reform Committee seeks “all statements of financial condition, annual statements, periodic financial reports, and independent auditors’ reports” in Mazars’s possession, as well as supporting documentation and related communications. It covers Trump’s individual finances as well as those of the Trump Organization over an eight-year period.The panel says it wants the documents because it is considering revising the federal ethics-in-government laws. Trump’s lawyers say the primary purpose is law enforcement, something they say is beyond Congress’s legislative powers.“This is a case of firsts,” Trump said in his new . “It is the first time that Congress has subpoenaed personal records of a sitting president. It is the first time that Congress has issued a subpoena, under the guise of its legislative powers, to investigate the president for illegal conduct. And it is the first time a court has upheld any congressional subpoena for any sitting president’s records of any kind.”In the New York case, Manhattan District Attorney Cyrus Vance Jr. is investigating whether Trump’s business falsified records to disguise hush payments to two women who claimed they had sex with Trump before he took office. In an appeal filed last month, Trump contended that presidents have broad immunity from criminal investigations while in office.In the Deutsche case, two other House committees are seeking financial records for Trump, his children and the Trump organization. Those committees say they have a variety of legislative interests and are investigating money laundering, terrorist financing and Russian efforts to influence U.S. elections.The new case is Trump v. Mazars, 19-715. The New York case is Trump v. Vance, 19-635.(Adds case names and numbers in last paragraph)To contact the reporter on this story: Greg Stohr in Washington at email@example.comTo contact the editors responsible for this story: Joe Sobczyk at firstname.lastname@example.org, Laurie Asséo, Ros KrasnyFor more articles like this, please visit us at bloomberg.com©2019 Bloomberg L.P.
The FDA grants Breakthrough Therapy designation to Bristol-Myers Squibb's (BMY) Orencia for the prevention of moderate-to-severe acute GvHD in hematopoietic SCT from unrelated donors.
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
Better-than-expected earnings performance and healthy prospects from key growth projects are contributing to Agnico Eagle's (AEM) performance.